Bio-Innovation Initiatives

Scientists have discovered a molecular motor inside bacteria that looks exactly like the electric motors we use every day. These are not just any motors; they are made of protein complexes and can spin both clockwise and counterclockwise, enabling bacteria like sperm to move similarly to man-made electric motor-powered machines. What's truly remarkable is how nature and human engineers independently developed similar designs for rotary motion. But here's the cool part: researchers are using cryo-electron microscopy to see these motors in insane detail. Basically, they flash-freeze bacteria samples and bombard them with electrons, capturing thousands of 2D images. As described by one of the researchers, it's just like taking thousands of iPhone Live Photos of something impossibly small. Now, then, they use AI to reconstruct these 2D images into 3D models. And what's mind-blowing is how the resolution is so good they can even see individual atoms and their bonds. However, why does this all matter?? well, understanding these spinning motors could revolutionize how we fight diseases. instead of killing bacteria, we might just stop them from moving with what these researchers call "lethargy biotics". Where you treat infections by making bacteria too lazy to spread or create super-precise drug delivery systems based on these natural motors.

400 million tons of plastic. Produced every single year. Less than 10% of all plastic ever made has been recycled. The rest sits in landfills. Floats in oceans. Breaks into microplastics. Persists for centuries. In 2008, a group of Yale students walked into the Ecuadorian Amazon. They collected endophytic fungi — organisms that live quietly inside plant tissues. One species stood out. Pestalotiopsis microspora. Jonathan Russell and colleagues published their findings in Applied and Environmental Microbiology in 2011. This fungus can degrade polyurethane. It uses polyurethane as its sole carbon source. Its only food. The enzyme responsible is a serine hydrolase. It breaks the polymer bonds. The critical detail: it works under anaerobic conditions. No oxygen required. That matters because the interior of a landfill is anaerobic. Dark. Compressed. No air. Most plastic degradation methods require UV light, oxygen, or extreme heat. This fungus needs none of those. Think about that. And P. microspora is not alone. Aspergillus tubingensis, isolated from a waste site in Pakistan, degrades polyester polyurethane on agar plates (Khan et al., Environmental Pollution, 2017). And the field goes beyond plastic. Mycoremediation uses fungi to break down oil spills, pesticides, industrial dyes, heavy metals. White-rot fungi produce enzymes that dismantle molecules nothing else in nature can handle. What stopped me: This research is still experimental. Nobody has deployed fungal plastic degradation at industrial scale yet. But the biology is there. The enzymes exist. The organisms are already doing it in the lab. The Multiplication Effect: 1 fungus degrading plastic in a lab = proof the biology works 10 species identified with similar abilities = a toolkit emerging 100 landfills deploying fungal bioremediation = the kingdom gets to work At scale = we stop burying the problem and start digesting it We've spent decades asking how to manage plastic waste. Maybe the answer was already here. Waiting in the soil. Inside a leaf. Patient. Do you see other examples where nature helps us to solve our biggest problems? Sources: Russell et al. (Applied and Environmental Microbiology, 2011), Geyer et al. (Science Advances, 2017), Khan et al. (Environmental Pollution, 2017)

Finland discovered bacteria that eat nuclear waste — cleaning radioactive sites in decades instead of millennia ☢️ Scientists at University of Helsinki identified extremophile bacteria in uranium mines that metabolize radioactive isotopes, converting dangerous nuclear waste into stable, non-radioactive compounds. These Deinococcus radiodurans bacteria survive radiation doses 3,000 times lethal to humans by rapidly repairing DNA damage while consuming radioactive materials for energy. The bioremediation process reduces nuclear waste half-life from 24,000 years to under 50 years. Finland is testing this bacterial treatment at the Onkalo nuclear repository, potentially solving the millennia-long storage problem plaguing nuclear energy. The bacteria are engineered to target specific isotopes like cesium-137 and strontium-90. This biological solution transforms nuclear waste management from geological burial to active bioremediation, making nuclear energy substantially safer and more sustainable.

I am tremendously excited about the real-world impact of our latest publication on #AI #Biomarkers in Nature Medicine: https://lnkd.in/dv-7aS7Y Even in the US barely half of #lungcancer patients are tested for #EGFR mutations, for which targeted therapies readily exist. We have worked for many, many years now to try to overcome this gap with AI for H&E slides to offer patients a fast and cost-effective solution to get the right treatment. The point of this work is not only that we actually built it, but that Gabriele Campanella and Chad Vanderbilt organized a consortium and created the infrastructure for the first real-world, real-time deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection. 𝙋𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚𝙡𝙮!   𝐌𝐞𝐞𝐭 𝐄𝐀𝐆𝐋𝐄 (EGFR AI Genomic Lung Evaluation): ✅ 𝟎.𝟖𝟗 𝐀𝐔𝐂 in a 𝐩𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 silent trial with clinical-grade performance. 🌍 Generalizes 𝐚𝐜𝐫𝐨𝐬𝐬 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐢𝐧𝐞𝐧𝐭𝐬 with robustness and reproducibility. 🔬 Validated on 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐡𝐨𝐫𝐭𝐬, 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐢𝐨𝐧𝐬, 𝐚𝐧𝐝 𝐬𝐜𝐚𝐧𝐧𝐞𝐫𝐬. 🧪 𝟒𝟑% 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐫𝐚𝐩𝐢𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐭𝐞𝐬𝐭𝐬, preserving biopsy tissue for full genomic profiling. ⚡ 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐮𝐧𝐝𝐞𝐫 𝟏 𝐡𝐨𝐮𝐫, compared to 2–3 weeks for NGS. 🚀 A foundational step toward regulatory approval and 𝐀𝐈-𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐰𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬.   We have worked on Computational Biomarkers in Pathology continuously for over a decade starting with AI for predicting SPOP in prostate cancer from H&E in 2015, but seeing everything come to fruition at such a scale in 2025 is very humbling. AI, when done right, can give real, tangible help to cancer patients. 𝑰𝒕 𝒊𝒔 𝒐𝒖𝒓 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒊𝒃𝒊𝒍𝒊𝒕𝒚 𝒕𝒐 𝒎𝒂𝒌𝒆 𝒊𝒕 𝒂 𝒓𝒆𝒂𝒍𝒊𝒕𝒚! I am deeply grateful to everyone on this most amazing team: Gabriele Campanella, Neeraj Kumar, Ph.D., Swaraj Nanda, Siddharth Singi, Eugene Fluder, Ricky Kwan, Silke Mühlstedt, Nicole  Pfarr, Peter Schüffler, Ida Häggström, Noora Neittaanmäki, Levent Akyürek, Alina Basnet, Tamara Jamaspishvili, Michel Nasr, Matthew Croken, Fred Hirsch, Arielle Elkrief, Helena Yu, Orly Ardon, Greg Goldgof, Meera Hameed, Jane Houldsworth, Maria E. Arcila, Chad Vanderbilt #AI #ComputationalPathology #Biomarkers #AIinHealthcare #DigitalPathology #PrecisionMedicine #LungCancer #EGFR #NatureMedicine #FoundationModels #EAGLEModel #EAGLE #Oncology

What if we could clean the earth without a single machine or chemical, just with plants? That’s what phytoremediation does. It’s nature’s silent clean-up system where roots, leaves, and microbes work together to remove or neutralize contaminants from soil and water. This infographic reveals how plants do it: 🪴 Phytoextraction – Roots absorb metals, which move up and accumulate in leaves. 🌱 Phytostabilization – Roots lock pollutants in place, stopping their spread. 🍃 Phytodegradation – Enzymes in roots and leaves break down toxins into harmless compounds. 🌾 Phytostimulation – Root exudates feed microbes that degrade pollutants. 💨 Phytovolatilization – Plants release transformed gases safely through leaves. It’s slow but self-sustaining, turning plants into living detox units that restore balance over time. If soil can heal itself with a little biological help, maybe our systems can too. Would you support using phytoremediation in urban lands, mining zones, or farms? Let’s talk about where this could make the biggest impact. (Infographic re-illustrated by Jagdish Patel ©, adapted from the work of Favas et al., 2014, Phytoremediation of Soils Contaminated with Metals and Metalloids at Mining Areas, DOI: 10.5772/57469.) #SoilHealth #Phytoremediation

A study of 100 fields reveals that even after 20 years of organic management, soils contain up to 16 different pesticide compounds—disrupting microbial communities and undermining productivity long after application stops. Fields were analyzed across the agricultural spectrum—from conventional operations to established organic farms. Certified organic soils contained significant levels of atrazine, chloridazon, and carbendazim (a compound linked to declining reproductive health). The data contradicts what's on pesticide labels. Atrazine's official half-life (6-108 days) suggests quick breakdown, but field measurements show it persists for decades. Our current models dramatically underestimate how long these compounds actually remain in soil systems. This isn't just about chemical presence—it's about ecosystem function. The study identified a strong negative correlation between pesticide residues and beneficial soil microorganisms. Specifically, mycorrhizal fungi showed significant decline in pesticide-affected soils. A critical insight: pesticide presence better predicted soil biological health than traditional factors like fertilization practices. This suggests our understanding of what drives soil fertility needs revision to account for these long-term chemical impacts. The implications challenge organic certification frameworks, which focus on current management but may overlook historical contamination. A "chemical-free" farm might contain decades of persistent compounds affecting soil function regardless of current practices. Fortunately, biological systems offer powerful remediation solutions: MICROBIAL REMEDIATION: microbes that consume pesticides, enhanced by adding nutrients or introducing specialized degraders ENZYME PATHWAYS that transform compounds into less toxic forms PHYTOREMEDIATION: Plants like Kochia scoparia remediate atrazine through uptake and by stimulating specialized microbial communities at their roots The most effective method is an integrated approach. Plant-microbe partnerships create effective remediation systems where plants fuel microbial activity and microbes enhance plant growth—a synergistic relationship that accelerates cleanup beyond what either could achieve alone. This research challenges the conventional-to-organic transition period. Rather than passive waiting periods, conversion should include active remediation strategies tailored to specific field conditions and contamination profiles. Agricultural soils have much longer chemical memories than previously understood. Biological systems—microbes, enzymes, plants—offer sophisticated remediation pathways that can restore soil ecological function while maintaining productive agricultural systems.

Probably, one of the largest collaborative efforts in biotech, since the Human Genome Project: the Human Cell Atlas has arrived! 🧬 I think the Human Cell Atlas (HCA) is a pretty monumental leap in systems biology, an international effort involving 3,600 researchers from 102 countries, has released its first draft atlas of human cells. This isn’t just another dataset—this is the blueprint of human biology, built cell by cell, tissue by tissue, organ by organ. The HCA integrated data from 62 million cells, sourced from 9,100 donors, spanning every stage of human development—embryonic to adult. Researchers organized their work into 18 Biological Networks, focusing on key organs like the lung, nervous system, and eye. Some of the tools like single-cell RNA sequencing, spatial transcriptomics, and multi-omics were combined to profile and map cells with unprecedented precision. Notably, Google provided essential cloud infrastructure and AI tools like scTab (for annotation) and SCimilarity (for cell similarity searches), helping researchers handle vast and complex datasets efficiently. It is also important that local scientists and the HCA Ethics Working Group put efforts to make sure data represented populations globally, prioritizing equity and open access. Now, how can we use it, practically speaking? Here I picked some of the key aspects that might be very useful for the biotech community: ✅ Precise Target Discovery: Pinpoint disease-specific cell types and biomarkers to create highly targeted therapies. ✅ Better Disease Models: Build realistic organoids and in vitro models informed by detailed cell maps for accurate drug testing. ✅ Personalized Medicine: Utilize data from diverse populations to design therapies tailored to genetic and environmental variations. ✅ Safer Drugs: Analyze tissue-specific metabolism to predict and avoid adverse drug effects. ✅ AI-Driven Insights: Tap into machine-learning tools like PopV and SCimilarity to accelerate discovery and refine findings. I believe, the Atlas could be a playing ground for other AI tools and new workflows! ✅ Early Diagnosis: Identify subtle gene expression changes for early detection of diseases like cancer or neurodegenerative disorders. If you're in biotech, drug discovery, or systems biology, this resource is now open and available—check it out! Link in the comments 👇 Image source:  Springer Nature

This paper is wild. After 3 rounds of directed evolution, they converted a DNA polymerase into an enzyme that can do: - RNA synthesis - Reverse transcription - Synthesis of "unnatural" nucleotides - Synthesis of DNA-RNA chimeras One of the best papers I’ve read recently. For context: In nature, it is DNA polymerase that takes a DNA sequence as a template and then copies it. These enzymes are crucial in replicating the genome for cell division, and they are EXTREMELY specific for DNA over RNA. This is key because RNA nucleotides are present in the cell at concentrations ~100x higher than DNA nucleotides, so the enzyme has evolved clever strategies to select one over the other. RNA polymerases, for comparison, are the enzymes that take a DNA sequence as template and then convert it into RNA. They are involved in gene expression, for example. To convert a DNA polymerase into an RNA polymerase (and all the other functions I mentioned earlier), the authors did a fairly straightforward directed evolution experiment. First, they took four DNA polymerase enzymes belonging to various archaea. These DNA polymerases don’t check for DNA vs. RNA as stringently as other types of cells, so they’re a good starting point to evolve RNA polymerases. The authors inserted some targeted mutations into these enzymes, based on known mutations in the literature. For example, they swapped the amino acid at position 409 for a smaller amino acid, thus removing a “gate” that keeps RNA building blocks from entering the enzyme. Next, they took the four genes encoding these DNA polymerases and cut them up into 12 segments each. They randomly stitched these 12 segments together — from the four different genes — to build millions of unique variants. Each shuffled gene was inserted into an E. coli cell. Then, they grew up these cells (each carrying a unique polymerase) and put them into microfluidic droplets. A device isolates each droplet, lyses the cell open, and releases the polymerase. The droplet also contains RNA building blocks and a DNA template, encoding a fluorescent reporter. If the polymerase begins synthesizing RNA, it will produce a detectable signal. They screened about 100 million droplets in 10 hours of work, searching for those with a signal. For each well that yields a fluorescent signal, the researchers isolated the DNA and sequenced it to figure out which polymerase it was. They repeated this 3x times, finally isolating a really excellent RNA polymerase variant which they called "C28." C28 has 39 mutations compared to the wildtype enzymes. It incorporates about 3.3 nucleotides of RNA per second, with 99.8% fidelity. The crazy thing is that this enzyme can also copy DNA or RNA templates back into DNA (reverse transcription), or use chimeric DNA-RNA molecules as a template and amplify them. It is just a super versatile polymerase that can act on DNA, RNA, or modified nucleotides, to build just about anything.

Drug deals help pharma giants move the needle 💉 The bio and pharma partnership landscape is intensifying – with Bristol-Myers Squibb and BioNTech’s partnership the latest in a flurry of activity in the space. Bristol-Myers Squibb has been extraordinarily active in forming strategic partnerships, particularly in cutting-edge therapeutic areas. Recent major deals include: AI and Technology Partnerships ↳Perpetual Medicines: $55 million upfront plus $55 million equity investment, with up to $3.5 billion in potential milestone payments for cell therapy development using prime editing technology ↳VantAI: Partnership for molecular glues development using generative AI, with potential for up to $674 million in research milestone payments ↳Terray Therapeutics: Multi-target collaboration leveraging the tNova platform for small molecule therapeutics discovery Broader Therapeutic Focus ↳BioArctic: $100 million upfront with up to $1.25 billion in milestone payments for Alzheimer's drug licensing ↳Scenic Biotech: Research collaboration utilizing Cell-Seq platform for drug target development This aggressive partnership strategy reflects Bristol-Myers Squibb's focus on "predictive science to reduce drug development costs and expedite treatment discovery", as the company transitions from legacy products to its growth portfolio, which now accounts for over half of its revenue. Broader Industry Trends The partnership intensity reflects broader market dynamics in the AI-derived biological drugs space, which has seen $2.9 billion in funding over the past two years as companies like Bristol-Myers Squibb seek to leverage AI for more efficient drug development. Based on recent partnership activity, six key therapeutic areas are driving the highest-value strategic alliances, with oncology leading the pack in terms of both deal size and frequency. 1. Oncology 2. AI-Powered Drug Discovery 3. Immunology 4. Neuroscience & CNS Disorders 5. Obesity & Metabolic Diseases 6. Genetic Therapeutics These therapeutic areas reflect broader market dynamics where AI integration has become the common denominator, enabling more efficient drug discovery across all categories. Increased partnership volume demonstrates how established pharma companies are securing access to next-generation immunotherapies through strategic alliances in addition to internal R&D and acquisitions. As the race for the oncology market intensifies, expect more deals across partnerships, investments, and M&A.

As JPM draws to a close, one of the biggest topics is whether BioPharma companies will move fast enough to refill their pipelines ahead of the biggest-ever set of LOEs in the coming years. Looking back on the last 5 years provides some good perspective on major new drug launches and what they've delivered. Worth noting this graphic focuses exclusively on first FDA or EMA approvals of new molecular or biologic entities (NME/NBE) between 2021 and 2025, excluding label expansions, new formulations, dose changes, combinations of existing drugs, and other lifecycle management activities. A few themes stand out. Even among the largest pharmaceutical companies, most years deliver only one or two true new molecular launches, and several years deliver none. Rather than pursuing broad portfolios of early-stage risk, companies are concentrating capital and R&D effort into fewer, higher-conviction programs, often built around well-validated biology, genetically defined patient populations, or platforms with repeatability potential. Oncology remains the dominant engine of new molecules, but the nature of innovation has shifted. Recent launches increasingly reflect mechanistic refinement rather than broad class creation. Targeted therapies, bispecific antibodies, and ADCs dominate, with differentiation driven by biomarker precision, toxicity management, and execution rather than target novelty alone. Assets such as Datroway, Emrelis, Columvi, and Talvey illustrate how mature modalities are being optimized for real-world use. Immunology and rare disease continue to attract focused molecular innovation, particularly where disease biology is well characterized and endpoints are measurable. Products like Rhapsido, targeting chronic spontaneous urticaria, and Vanrafia, developed for IgA nephropathy, exemplify a strategy centered on specialist-managed populations rather than broad primary-care indications. Small molecules have quietly reasserted their strategic importance. Despite sustained investment in complex biologics, many of the most scalable new launches remain oral agents, spanning endocrinology, dermatology, cardio-renal disease, and neurology. Cibinqo, Litfulo, and Inlurio highlight how chemistry-driven innovation continues to underpin commercial impact.